Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
Símbolo de cotizaciónINDV
Nombre de la empresaIndivior PLC
Fecha de salida a bolsaDec 24, 2014
Director ejecutivoCiaffoni (Joseph J)
Número de empleados1030
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 24
Dirección234 Bath Road
CiudadSLOUGH
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalSL1 4EE
Teléfono448043791090
Sitio Webhttps://www.indivior.com/en
Símbolo de cotizaciónINDV
Fecha de salida a bolsaDec 24, 2014
Director ejecutivoCiaffoni (Joseph J)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos